These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20620727)

  • 21. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
    Butler MJ; Eccleston D; Clark DJ; Ajani AE; Andrianopoulos N; Brennan A; New G; Black A; Szto G; Reid CM; Yan BP; Shaw JA; Dart AM; Duffy SJ;
    Am Heart J; 2009 May; 157(5):899-907. PubMed ID: 19376319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis.
    Biondi-Zoccai GG; Agostoni P; Testa L; Abbate A; Parisi Q; Burzotta F; Trani C; Mongiardo R; Vassanelli C; Biasucci LM
    Minerva Cardioangiol; 2004 Jun; 52(3):195-208. PubMed ID: 15194981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor.
    Tanaka A; Sakakibara M; Okumura S; Okada K; Ishii H; Murohara T
    J Cardiol; 2012 Jul; 60(1):7-11. PubMed ID: 22445597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
    Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
    Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interaction between clopidogrel and proton pump inhibitors.
    Khalique SC; Cheng-Lai A
    Cardiol Rev; 2009; 17(4):198-200. PubMed ID: 19525682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
    Ma TK; Lam YY; Tan VP; Kiernan TJ; Yan BP
    Pharmacol Ther; 2010 Feb; 125(2):249-59. PubMed ID: 19919843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
    Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
    Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
    Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
    Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
    Chen M; Wei JF; Xu YN; Liu XJ; Huang DJ
    Cardiovasc Ther; 2012 Oct; 30(5):e227-33. PubMed ID: 21884023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
    Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
    Wolak A; Amit G; Cafri C; Gilutz H; Ilia R; Zahger D
    Int J Cardiol; 2005 Sep; 103(3):293-7. PubMed ID: 16098392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.
    Kwok CS; Loke YK
    Aliment Pharmacol Ther; 2010 Apr; 31(8):810-23. PubMed ID: 20102352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Eur J Clin Invest; 2012 Mar; 42(3):266-74. PubMed ID: 21834799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
    Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.